fig3

Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population

Figure 3. (A) Probability of progression-free survival according to histology. Median PFS: 15.2 months (clear cell histology) vs. 8.2 months (non-clear cell histology) HR = 1.84 (95% CI: 0.9-3.76); P = 0.089; (B) probability of overall survival according to histology: 26.8 months (clear cell histology) (95% CI: 20.1-30.5) vs. 14.2 months (non-clear cell histology) (95% CI: 0-29.0) HR = 3.41 (95% CI: 1.6-7.3; P = 0.001). PFS: progression-free survival; CI: confidence interval; HR: hazard ratio

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/